US Stem Cell (USRM) Stock Price & Analysis
USRM Stock Chart & Stats
- Day’s Range
- $0.01 - $0.01
- 52-Week Range
- N/A
- Previous Close
- $0.01
- Volume
- 54.80K
- Average Volume (3M)
- 1.55M
- Market Cap
- $64.15K
- Enterprise Value
- $9.01T
- Total Cash (Recent Filing)
- $5,133
- Total Debt (Recent Filing)
- $8.95M
- Price to Earnings (P/E)
- ―
- Beta
- -125.88
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
US Stem Cell News
USRM FAQ
What is US Stem Cell’s market cap?
When is US Stem Cell’s upcoming earnings report date?
How were US Stem Cell’s earnings last quarter?
Is US Stem Cell overvalued?
Does US Stem Cell pay dividends?
What is US Stem Cell’s EPS estimate?
How many shares outstanding does US Stem Cell have?
What happened to US Stem Cell’s price movement after its last earnings report?
Which hedge fund is a major shareholder of US Stem Cell?
What is the TipRanks Smart Score and how is it calculated?
Company Description
US Stem Cell
U.S. Stem Cell, Inc. is a biotechnology firm dedicated to the advancement and commercialization of autologous cellular therapies throughout the United States. Its core mission is to address a range of medical conditions, including both chronic and acute forms of heart damage, along with various vascular and autoimmune disorders. Among its leading experimental treatments are MyoCell, a clinical-stage therapy designed to utilize a patient's own muscle cells to regenerate scar tissue within the heart, aiming to enhance cardiac function for individuals suffering from chronic heart failure. Another significant offering is AdipoCell, a cell therapy also derived from the patient's own body, developed to combat conditions such as acute myocardial infarction, persistent heart ischemia, and ischemia affecting the lower limbs. The company's developmental pipeline also features MyoCell SDF-1, another autologous cellular therapy derived from muscle, intended to boost cardiac performance in chronic heart failure patients. Furthermore, U.S. Stem Cell is actively developing MyoCath, an innovative deflecting-tip needle injection catheter specifically engineered to deliver therapeutic cells directly into heart tissue, addressing chronic heart ischemia and congestive heart failure. Beyond its product development, the company offers a suite of services, including training programs in regenerative medicine and cell therapy for both medical professionals and patients. It also facilitates cell collection and storage, provides specialized kits for cell collection and treatment for both human and veterinary applications, and manages its own cell therapy clinic. This clinic delivers cellular treatments for a broad spectrum of conditions, such as neurological, autoimmune, orthopedic, and degenerative disorders. Previously known as Bioheart, Inc., the company adopted its current name, U.S. Stem Cell, Inc., in October 2015. Established in 1999, its corporate headquarters are situated in Sunrise, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael Tomas
- Employees
- 11
- Website
- www.us-stemcell.com
- Address
- 1560 Sawgrass Corporate Parkway, Sunrise, FL, 33323, US
